Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years [Phase 3]

View source ↗

Summary

Phase 3 trial update on immunogenicity and safety of one-dose meningococcal vaccine in healthy adults over 56; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Meningococcal vaccine (Neisseria meningitidis vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2017-04-28